Covered recipient · General Payments record
MICHAEL E MANNING
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$183,947.01
304 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $113,991.45 | 45 |
| Consulting Fee | $50,347.96 | 17 |
| Travel and Lodging | $10,911.01 | 35 |
| Food and Beverage | $5,997.77 | 202 |
| Honoraria | $2,660.00 | 2 |
| Education | $38.82 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CSL Behring | $41,134.16 | 49 |
| Takeda Pharmaceuticals U.S.A., Inc. | $31,543.13 | 46 |
| Novartis Pharmaceuticals Corporation | $25,409.63 | 35 |
| Pharming Healthcare, Inc. | $17,092.92 | 11 |
| Ionis Pharmaceuticals, Inc. | $16,271.83 | 20 |
| BioCryst US Sales Co., LLC | $10,826.71 | 15 |
| SANOFI US SERVICES INC. | $9,546.48 | 5 |
| AstraZeneca Pharmaceuticals LP | $8,384.21 | 17 |
| GlaxoSmithKline, LLC. | $5,536.19 | 29 |
| Regeneron Healthcare Solutions, Inc. | $4,505.42 | 9 |
| BioCryst Pharmaceuticals, Inc. | $4,215.60 | 2 |
| GENZYME CORPORATION | $3,150.19 | 17 |
| Blueprint Medicines Corporation | $2,866.96 | 5 |
| Genentech USA, Inc. | $2,612.37 | 7 |
| GC Biopharma USA, Inc. | $267.54 | 9 |
| PFIZER INC. | $196.99 | 8 |
| Grifols USA, LLC | $135.55 | 6 |
| ARS Pharmaceuticals Operations, Inc. | $81.87 | 3 |
| Amgen Inc. | $81.78 | 4 |
| Lilly USA, LLC | $25.21 | 1 |
| ADMA BioManufacturing LLC | $19.46 | 3 |
| ABBVIE INC. | $18.36 | 1 |
| Merck Sharp & Dohme LLC | $13.92 | 1 |
| Organon LLC | $10.53 | 1 |
Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL E MANNING
NPI 1396744249 · CMS profile ID 335771
Allopathic & Osteopathic Physicians / Allergy & Immunology
SCOTTSDALE, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1396744249?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL E MANNING, NPI 1396744249, CMS profile ID 335771. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396744249?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MICHAEL E MANNING, NPI 1396744249, CMS profile ID 335771. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396744249?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MICHAEL E MANNING, NPI 1396744249, CMS profile ID 335771, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1396744249?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
304 matching records · $183,947.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 304.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BioCryst US Sales Co., LLC | $60.70 | 10/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222002787 | CMS |
| BioCryst US Sales Co., LLC | $81.06 | 10/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222016630 | CMS |
| Ionis Pharmaceuticals, Inc. | $6.84 | 10/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786845 | CMS |
| Novartis Pharmaceuticals Corporation | $22.06 | 10/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606376 | CMS |
| BioCryst US Sales Co., LLC | $95.00 | 10/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222002783 | CMS |
| BioCryst US Sales Co., LLC | $464.97 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222006113 | CMS |
| BioCryst US Sales Co., LLC | $6,555.00 | 10/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222009728 | CMS |
| BioCryst US Sales Co., LLC | $113.98 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222013129 | CMS |
| BioCryst US Sales Co., LLC | $227.26 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222027018 | CMS |
| Grifols USA, LLC | $24.93 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249583942 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $8.67 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223804288 | CMS |
| Lilly USA, LLC | $25.21 | 10/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186815519 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.28 | 10/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223859747 | CMS |
| PFIZER INC. | $29.70 | 10/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229236061 | CMS |
| CSL Behring | $740.66 | 10/12/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232343696 | CMS |
| Novartis Pharmaceuticals Corporation | $79.60 | 10/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606390 | CMS |
| Novartis Pharmaceuticals Corporation | $74.99 | 10/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606392 | CMS |
| Novartis Pharmaceuticals Corporation | $35.00 | 10/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606394 | CMS |
| Novartis Pharmaceuticals Corporation | $50.00 | 10/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606396 | CMS |
| Novartis Pharmaceuticals Corporation | $32.53 | 10/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606398 | CMS |
| Novartis Pharmaceuticals Corporation | $195.92 | 10/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200606388 | CMS |
| Novartis Pharmaceuticals Corporation | $13.33 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200598611 | CMS |
| CSL Behring | $28.39 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232343826 | CMS |
| GENZYME CORPORATION | $9.52 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233255277 | CMS |
| Ionis Pharmaceuticals, Inc. | $2,780.00 | 10/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786841 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $4.74 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223801021 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.43 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223852452 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.43 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223922788 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $62.00 | 10/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224097168 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $448.18 | 10/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224098166 | CMS |
| Pharming Healthcare, Inc. | $28.18 | 10/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200800225 | CMS |
| GC Biopharma USA, Inc. | $15.05 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248222751 | CMS |
| Ionis Pharmaceuticals, Inc. | $4,170.00 | 09/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786838 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.47 | 09/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223797794 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.86 | 09/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223798392 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.70 | 09/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223838114 | CMS |
| GENZYME CORPORATION | $19.65 | 09/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233255309 | CMS |
| Ionis Pharmaceuticals, Inc. | $4,170.00 | 09/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786834 | CMS |
| CSL Behring | $26.25 | 09/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232343822 | CMS |
| Ionis Pharmaceuticals, Inc. | $120.86 | 09/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786830 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.17 | 09/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223820307 | CMS |
| CSL Behring | $26.78 | 09/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232343820 | CMS |
| Ionis Pharmaceuticals, Inc. | $15.72 | 09/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786820 | CMS |
| Ionis Pharmaceuticals, Inc. | $50.00 | 09/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786823 | CMS |
| Ionis Pharmaceuticals, Inc. | $50.00 | 09/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786826 | CMS |
| Ionis Pharmaceuticals, Inc. | $75.39 | 09/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786806 | CMS |
| Ionis Pharmaceuticals, Inc. | $256.71 | 09/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786810 | CMS |
| Ionis Pharmaceuticals, Inc. | $19.44 | 09/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786812 | CMS |
| Ionis Pharmaceuticals, Inc. | $271.57 | 09/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246786816 | CMS |
| CSL Behring | $14.11 | 09/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232343728 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $35,012.73 | 31 |
| PY2025 | Principal investigator | $71,701.26 | 184 |
| PY2024 | Principal investigator | $219,912.00 | 272 |
| PY2023 | Recipient | $187.86 | 1 |
| PY2023 | Principal investigator | $266,648.88 | 344 |
| PY2022 | Principal investigator | $244,963.26 | 250 |
| PY2021 | Principal investigator | $790,224.20 | 333 |
| PY2020 | Principal investigator | $320,445.15 | 137 |
| PY2019 | Principal investigator | $223,432.68 | 70 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
215 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $65.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791996 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $77.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792001 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $97.50 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792006 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $150.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792009 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $200.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792013 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $250.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792016 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $260.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792019 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $292.50 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792023 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $325.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792027 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $400.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792031 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $100.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792035 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $231.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792038 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $300.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792042 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $800.00 | 12/30/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246792045 |
| Recipient | CSL Behring | $50.00 | 12/22/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664255 |
| Recipient | CSL Behring | $135.00 | 12/22/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664257 |
| Recipient | CSL Behring | $350.00 | 12/22/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664259 |
| Recipient | CSL Behring | $391.00 | 12/15/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664253 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,614.14 | 12/03/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192167719 |
| Recipient | CSL Behring | $50.00 | 11/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664249 |
| Recipient | CSL Behring | $405.00 | 11/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664251 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 11/17/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184261591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 11/03/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184257037 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,000.00 | 10/23/2025 | Non-covered Recipient Entity ALLERGY ASTHMA IMMUNOLOGY ASSOCIA LTD | A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. | No dispute reported | 06/30/2026 | 1190309082 |
| Recipient | CSL Behring | $1,688.00 | 10/22/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $136.00 | 10/15/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184250113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 10/15/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184250115 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,600.00 | 10/14/2025 | Non-covered Recipient Entity Allergy, Asthma And Immunology Associates, Ltd | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226091530 |
| Recipient | CSL Behring | $1,079.73 | 10/02/2025 | Covered Recipient Physician | Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study) | No dispute reported | 06/30/2026 | 1252664245 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $250.00 | 09/19/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787503 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $300.00 | 09/19/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787507 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $500.00 | 09/19/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787510 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $600.00 | 09/19/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787514 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,200.00 | 09/19/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787518 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,000.00 | 09/19/2025 | Non-covered Recipient Entity ONE OF A KIND CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787522 |
| Recipient | CSL Behring | $3,439.00 | 09/15/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664243 |
| Principal investigator 1 | CSL Behring | $212.67 | 09/15/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673376 |
| Recipient | CSL Behring | $5,000.00 | 09/10/2025 | Covered Recipient Physician | Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study) | No dispute reported | 06/30/2026 | 1252664239 |
| Recipient | CSL Behring | $4,500.00 | 09/10/2025 | Covered Recipient Physician | Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study) | No dispute reported | 06/30/2026 | 1252664241 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,020.00 | 08/22/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192167715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 08/21/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184229559 |
| Principal investigator 1 | CSL Behring | $220.13 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673348 |
| Principal investigator 1 | CSL Behring | $42.73 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673350 |
| Principal investigator 1 | CSL Behring | $105.60 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673352 |
| Principal investigator 1 | CSL Behring | $373.01 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673354 |
| Principal investigator 1 | CSL Behring | $315.68 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673356 |
| Principal investigator 1 | CSL Behring | $450.00 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673358 |
| Principal investigator 1 | CSL Behring | $643.66 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673360 |
| Principal investigator 1 | CSL Behring | $760.56 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673362 |
| Principal investigator 1 | CSL Behring | $448.84 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673364 |
| Principal investigator 1 | CSL Behring | $42.73 | 08/11/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673366 |
| Principal investigator 1 | CSL Behring | $261.12 | 08/01/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673188 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,319.00 | 07/23/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167695 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $475.00 | 07/14/2025 | Non-covered Recipient Entity Allergy, Asthma And Immunology Associates, Ltd | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226091508 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,765.00 | 07/02/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192165569 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,030.00 | 07/02/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192167707 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $479.06 | 07/02/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184212605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 06/30/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184212107 |
| Principal investigator 1 | CSL Behring | $220.13 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673332 |
| Principal investigator 1 | CSL Behring | $42.73 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673334 |
| Principal investigator 1 | CSL Behring | $105.60 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673336 |
| Principal investigator 1 | CSL Behring | $373.01 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673338 |
| Principal investigator 1 | CSL Behring | $315.68 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673340 |
| Principal investigator 1 | CSL Behring | $3,600.00 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673342 |
| Principal investigator 1 | CSL Behring | $450.00 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673344 |
| Principal investigator 1 | CSL Behring | $85.46 | 06/12/2025 | Non-covered Recipient Entity Allergy Asthma and Immunology Associates South Scottsdale Office | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252673346 |
| Principal investigator 1 | CSL Behring | $962.22 | 06/11/2025 | Non-covered Recipient Entity VA Minneapolis health care | An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency | No dispute reported | 06/30/2026 | 1252670126 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $417.00 | 06/06/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.50 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184202949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184202977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $187.50 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184202981 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203403 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203681 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $952.00 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $43.75 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 06/04/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184203837 |
| Recipient | CSL Behring | $50.00 | 06/02/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664233 |
| Recipient | CSL Behring | $135.00 | 06/02/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664235 |
| Recipient | CSL Behring | $400.00 | 06/02/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664237 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 06/02/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167703 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 05/27/2025 | Non-covered Recipient Entity Allergy, Asthma And Immunology Associates, Ltd | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226091501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 05/19/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184196349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 05/14/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184194529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 05/07/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $479.06 | 04/28/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184190441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 04/23/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184187993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185041 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48.75 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185045 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.50 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $43.75 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $187.50 | 04/18/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184185055 |
| Recipient | CSL Behring | $1,751.00 | 04/11/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664231 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,258.00 | 04/02/2025 | Non-covered Recipient Entity Allergy, Asthma And Immunology Associates, Ltd | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226091497 |
| Recipient | CSL Behring | $50.00 | 03/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664223 |
| Recipient | CSL Behring | $400.00 | 03/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664225 |
| Recipient | CSL Behring | $950.00 | 03/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664227 |
| Recipient | CSL Behring | $2,004.00 | 03/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664229 |
| Recipient | CSL Behring | $50.00 | 03/07/2025 | Covered Recipient Physician | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252664211 |
| Recipient | CSL Behring | $185.00 | 03/07/2025 | Covered Recipient Physician | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252664213 |
| Recipient | CSL Behring | $400.00 | 03/07/2025 | Covered Recipient Physician | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252664215 |
| Recipient | CSL Behring | $665.00 | 03/07/2025 | Covered Recipient Physician | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252664217 |
| Recipient | CSL Behring | $1,300.00 | 03/07/2025 | Covered Recipient Physician | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252664219 |
| Recipient | CSL Behring | $1,500.00 | 03/07/2025 | Covered Recipient Physician | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252664221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 02/27/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184155830 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $956.70 | 02/25/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167689 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154726 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154730 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154732 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154734 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154736 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154738 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/20/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184154742 |
| Recipient | CSL Behring | $5,317.00 | 02/19/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153898 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153900 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153902 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153904 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153906 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153908 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/13/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184153912 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151841 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151843 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151845 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151849 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151857 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151859 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151867 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184151999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152386 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152394 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152398 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152402 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152408 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152418 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.25 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.50 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.75 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.00 | 02/05/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152426 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,565.00 | 02/04/2025 | Non-covered Recipient Entity Allergy, Asthma And Immunology Associates, Ltd | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226091492 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $479.06 | 01/31/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184151549 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,186.76 | 01/28/2025 | Non-covered Recipient Entity MANNINGS 8TH AVENUE, INC | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190301621 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,647.00 | 01/24/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192165573 |
| Recipient | CSL Behring | $1,783.00 | 01/17/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664207 |
| Recipient | CSL Behring | $100.00 | 01/15/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664199 |
| Recipient | CSL Behring | $135.00 | 01/15/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664201 |
| Recipient | CSL Behring | $350.00 | 01/15/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664203 |
| Recipient | CSL Behring | $400.00 | 01/15/2025 | Covered Recipient Physician | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252664205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147425 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $187.50 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147427 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48.75 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147443 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $43.75 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 01/09/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184147449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.69 | 01/02/2025 | Non-covered Recipient Entity ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144676 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,027.34 | 01/01/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES, LTD. | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190309064 |